BridgeBio Pharma (FRA:2CL) Moat Score: 5/10 (As of Jun. 30, 2026)


FRA:2CL BridgeBio Pharma Inc FRA:2CL
69 GF Score
Price €61.46
GF Value €122.43
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is BridgeBio Pharma Moat Score?

BridgeBio Pharma FRA:2CL +2.55% 69 Moat Score is 5 as of Jun. 30, 2026. GuruFocus rates FRA:2CL with a GF Score™ of 69/100 and a GF Value™ of €122.43 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,401 Biotechnology companies, BridgeBio Pharma ranks better than 96.72% on this metric.

BridgeBio Pharma has the Moat Score of 5, which implies that the company might have Narrow Moat - Solid narrow moat.

BridgeBio Pharma has Narrow Moat: BridgeBio Pharma Inc has a solid narrow moat due to its valuable intellectual property and strong R&D capabilities. However, it faces challenges in achieving durable cost advantages and market leadership.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes BridgeBio Pharma might have Narrow Moat - Solid narrow moat.

BridgeBio Pharma  (FRA:2CL) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

BridgeBio Pharma Moat Score Related Terms

FRA:2CL vs EXEL, IONS, JAZZ: Moat Score Comparison

For the Biotechnology subindustry, BridgeBio Pharma's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BridgeBio Pharma Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BridgeBio Pharma's Moat Score distribution charts can be found below:

* The bar in red indicates where BridgeBio Pharma's Moat Score falls into.


FRA:2CL
69GF Score
BridgeBio Pharma Inc FRA:2CL
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 5 mean?
BridgeBio Pharma (FRA:2CL) has a Moat Score of 5 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, BridgeBio Pharma ranks #46 out of 1401 companies in the Biotechnology industry, placing it in the top 3.3%.
Is BridgeBio Pharma's Moat Score too high?
BridgeBio Pharma's current Moat Score is 5. The Biotechnology industry median Moat Score is 2.00. BridgeBio Pharma's value of 5 is 150% above this industry median. Based on the distribution chart, BridgeBio Pharma ranks #46 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BridgeBio Pharma has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BridgeBio Pharma's Moat Score compare to EXEL and IONS?
According to the Biotechnology industry distribution chart, BridgeBio Pharma ranks #46 out of 1401 companies for Moat Score. This places BridgeBio Pharma in the top 3% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. BridgeBio Pharma's value of 5 is 150% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BridgeBio Pharma's current Moat Score of 5 is 150% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BridgeBio Pharma's current Moat Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BridgeBio Pharma stock overvalued right now?
Based on GuruFocus' analysis, BridgeBio Pharma (FRA:2CL) is currently considered Possible Value Trap. The stock's GF Value™ is €122.43, compared to a current price of €61.46 — trading 49.8% below its estimated fair value. The current Moat Score is 5 and 150% above the Biotechnology industry median of 2.00. BridgeBio Pharma's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For BridgeBio Pharma (FRA:2CL), the current Moat Score is 5 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BridgeBio Pharma (FRA:2CL) Overvalued in 2026?

Based on GuruFocus' analysis, BridgeBio Pharma stock appears to be undervalued. The current stock price of €61.46 is trading 49.8% below its estimated GF Value™ of €122.43. GuruFocus considers BridgeBio Pharma to be Possible Value Trap.

Key valuation signals for FRA:2CL:

  • Moat Score: 5
  • GF Value™: €122.43 vs. price of €61.46 (49.8% below fair value)
  • GF Score™: 69/100 with 7 warning signs
  • Industry Position: 150% above the Biotechnology median (#46 of 1401)

No single metric tells the full story. See the FRA:2CL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BridgeBio Pharma Business Description

Other Exchanges BBIO:USA1BBIO:Italy
Address 3160 Porter Drive, Suite 250, Palo Alto, CA, USA, 94304
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
69GF Score

Get the complete analysis for FRA:2CL

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€61.46
Price
€122.43
GF Value